Will more aggressive BP control reduce the risk of CV outcomes? Finally, some answers.
Resistant hypertension? A hypertensive emergency? Select your strategy and then find out if the evidence supports it.
The practice of CVD risk estimation shifted radically in 2013. The ACC-AHA app helps you connect the new dots.
Our cardiologist blogger highlights PARTNER-2, HOPE-3, and sessions on women in cardiology at ACC.16.
Researchers presented several new findings about statins and non-statins at ACC.16. This brief roundup summarizes these and other noteworthy reports.
Highlights of four recent studies in hypertension, heart failure, preeclampsia expose vulnerable populations.
Find out what you know about how to avoid therapeutic inertia in treatment of hypertension.
Beta-blockers were one of the first modern medications used for the treatment of blood pressure. Before 1950, treatment options for hypertension were limited. The alphabet soup of medications -- reserpine, pentaquine, hydralazine, and guanethidine -- were notorious for inducing orthostasis, sedation, constipation, impotence, or blurry vision.
There is no compelling evidence that testosterone therapy increases or decreases cardiovascular risk, according to a new position statement from the American Academy of Clinical Endocrinologists (AACE).
The statement was issued in response to recent publications that have raised concern that testosterone replacement therapy (TRT) increases cardiovascular risks in men and media reports about the dangers of testosterone therapy.
Elevated blood pressure was associated with an increased risk for diabetes, according to an analysis of the electronic health records (EHRs) and a meta-analysis.